Fennec Pharmaceuticals (FENC) CEO Jeffrey Hackman Receives Award

What Happened Jeffrey S. Hackman, Chief Executive Officer of Fennec Pharmaceuticals (FENC), had 1,159 shares released from restriction on August 31, 2026. The filing reports the acquisition as an award/other acquisition (code A) at $0.00 per share, so no cash changed hands in this transaction.

Key Details

• Transaction date: 2026-08-31
• Transaction type/code: Award/release of restricted shares (A)
• Shares acquired: 1,159 shares at $0.00 per share (total reported value $0)
• Shares owned after transaction: Not specified in the filing
• Footnote: F1 — these shares were released from restriction from an award granted on 2025-03-28
• Filing timeliness: Report dated and filed 2026-08-31 (timely)

Context This was a vesting/release of previously granted restricted stock, not an open-market purchase or sale. Such releases are routine compensation events (not necessarily a bullish or bearish signal) and simply convert restricted awards into freely held shares for the insider.